Small-molecule modulation of Ras signaling

Nature Chemical Biology

Volumn 10, Issue 8, 2014, Pages 613-622

  Spiegel, Jochen ^a,b   Cromm, Philipp M ^a,b   Zimmermann, Gunther ^a,b   Grossmann, Tom N ^b,c   Waldmann, Herbert ^a,b  

^a MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY   (Germany)

^b TU DORTMUND UNIVERSITY   (Germany)

^c CHEMICAL GENOMICS CENTRE OF THE MAX PLANCK SOCIETY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GERANYLTRANSFERASE; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; K RAS PROTEIN; MCP 110; NEW DRUG; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; SULINDAC SULFIDE; UNCLASSIFIED DRUG;

ALLOSTERISM; ALPHA HELIX; CANCER RESEARCH; CATALYSIS; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

AMINO ACID SEQUENCE; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATE; HUMANS; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; MUTATION; PROTEIN CONFORMATION; PROTEIN KINASES; RAS PROTEINS; SIGNAL TRANSDUCTION; SMALL MOLECULE LIBRARIES;

EID: 84904721890     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1560     Document Type: Review

References (104)

1. Forbes, S.A. et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer. Nucleic Acids Res. 39, D945-D950 (2011).
2. Prior, I.A., Lewis, P.D. & Mattos, C.A. Comprehensive survey of Ras mutations in cancer. Cancer Res. 72, 2457-2467 (2012).
3. Helwick, C. Targeting KRAS in GI Cancers: the hunt for the Holy Grail in cancer research. Te ASCO Post, http://www.ascopost.com/issues/april-15-2012/ targeting-kras-in-gi-cancers-the-hunt-for-the-holy-grail-in-cancer-research. aspx (2012).
4. Wennerberg, K., Rossman, K.L. & Der, C.J. Te Ras superfamily at a glance. J. Cell Sci. 118, 843-846 (2005).
5. Cherfls, J. & Zeghouf, M. Regulation of Small GTPases by GEFs, GAPs, and GDIs. Physiol. Rev. 93, 269-309 (2013).
6. Vetter, I.R. & Wittinghofer, A. Te guanine nucleotide-binding switch in three dimensions. Science 294, 1299-1304 (2001).
7. Prior, I.A. & Hancock, J.F. Ras trafcking, localization and compartmentalized signalling. Semin. Cell Dev. Biol. 23, 145-153 (2012).
8. Pylayeva-Gupta, Y., Grabocka, E. & Bar-Sagi, D. RAS oncogenes: weaving a tumorigenic web. Nat. Rev. Cancer 11, 761-774 (2011).
9. Baines, A.T., Xu, D. & Der, C.J. Inhibition of Ras for cancer treatment: the search continues. Future Med. Chem. 3, 1787-1808 (2011).
10. Lito, P., Rosen, N. & Solit, D.B. Tumor adaptation and resistance to RAF inhibitors. Nat. Med. 19, 1401-1409 (2013).
11. Berndt, N., Hamilton, A.D. & Sebti, S.M. Targeting protein prenylation for cancer therapy. Nat. Rev. Cancer 11, 775-791 (2011).
12. Wang, Y., Kaiser, C.E., Frett, B. & Li, H.-y. Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators. J. Med. Chem. 56, 5219-5230 (2013).
13. Wang, W., Fang, G. & Rudolph, J. Ras inhibition via direct Ras binding- is there a path forward? Bioorg. Med. Chem. Lett. 22, 5766-5776 (2012).
14. Noonan, T., Brown, N., Dudycz, L. & Wright, G. Interaction of GTP derivatives with cellular and oncogenic ras-p21 proteins. J. Med. Chem. 34, 1302-1307 (1991).
15. Wolin, R., et al. Synthesis and evaluation of pyrazolo[3, 4-b]quinoline ribofuranosides and their derivatives as inhibitors of oncogenic Ras. Bioorg. Med. Chem. Lett. 6, 195-200 (1996).
16. Becher, I. et al. Afnity profling of the cellular kinome for the nucleotide cofactors ATP, ADP, and GTP. ACS Chem. Biol. 8, 599-607 (2013).
17. 2+-binding site of the guanine nucleotide-binding protein p21H-ras. J. Biol. Chem. 268, 923-929 (1993).
18. Freedman, T.S. et al. A Ras-induced conformational switch in the Ras activator Son of sevenless. Proc. Natl. Acad. Sci. USA 103, 16692-16697 (2006).
19. Taveras, A.G. et al. Ras oncoprotein inhibitors: the discovery of potent, ras nucleotide exchange inhibitors and the structural determination of a drug-protein complex. Bioorg. Med. Chem. 5, 125-133 (1997).
20. Ganguly, A.K. et al. Interaction of a novel GDP exchange inhibitor with the Ras protein. Biochemistry 37, 15631-15637 (1998).
21. Peri, F. et al. Design, synthesis and biological evaluation of sugar-derived Ras inhibitors. ChemBioChem 6, 1839-1848 (2005).
22. Sacco, E. et al. Binding properties and biological characterization of new sugar-derived Ras ligands. Med. Chem. Commun. 2, 396 (2011).
23. Patgiri, A., Yadav, K.K., Arora, P.S. & Bar-Sagi, D. An orthosteric inhibitor of the Ras-Sos interaction. Nat. Chem. Biol. 7, 585-587 (2011).
24. Sacco, E. et al. Novel RasGRF1-derived Tat-fused peptides inhibiting Ras-dependent proliferation and migration in mouse and human cancer cells. Biotechnol. Adv. 30, 233-243 (2012).
25. Gorfe, A.A., Grant, B.J. & McCammon, J.A. Mapping the nucleotide and isoform-dependent structural and dynamical features of Ras proteins. Structure 16, 885-896 (2008).
26. Grant, B.J. et al. Novel allosteric sites on Ras for lead generation. PLoS ONE 6, e25711 (2011).
27. Hocker, H.J. et al. Andrographolide derivatives inhibit guanine nucleotide exchange and abrogate oncogenic Ras function. Proc. Natl. Acad. Sci. USA 110, 10201-10206 (2013).
28. Hajduk, P.J. & Greer, J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov. 6, 211-219 (2007).
29. Maurer, T. et al. Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc. Natl. Acad. Sci. USA 109, 5299-5304 (2012).
30. Sun, Q. et al. Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation. Angew. Chem. Int. Ed. Engl. 51, 6140-6143 (2012).
31. Schöpel, M. et al. Bisphenol A binds to Ras proteins and competes with guanine nucleotide exchange: implications for GTPase-selective antagonists. J. Med. Chem. 56, 9664-9672 (2013).
32. Burns, M.C. et al. Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange. Proc. Natl. Acad. Sci. USA 111, 3401-3406 (2014).
33. Lim, S.M. et al. Terapeutic Targeting of Oncogenic K-Ras by a Covalent Catalytic Site Inhibitor. Angew. Chem. Int. Ed. Engl. 53, 199-204 (2014).
34. Ostrem, J.M., Peters, U., Sos, M.L., Wells, J.A. & Shokat, K.M. K-Ras(G12C) inhibitors allosterically control GTP afnity and efector interactions. Nature 503, 548-551 (2013).
35. Geyer, M. et al. Conformational Transitions in p21 Ras and in its complexes with the efector protein Raf-RBD and the GTPase activating protein GAP. Biochemistry 35, 10308-10320 (1996).
36. Spoerner, M., Herrmann, C., Vetter, I.R., Kalbitzer, H.R. & Wittinghofer, A. Dynamic properties of the Ras switch I region and its importance for binding to efectors. Proc. Natl. Acad. Sci. USA 98, 4944-4949 (2001).
37. 31P NMR spectroscopy. FEBS Lett. 578, 305-310 (2004).
38. Liao, J. et al. Two conformational states of Ras GTPase exhibit diferential GTP-binding kinetics. Biochem. Biophys. Res. Commun. 369, 327-332 (2008).
39. Spoerner, M., Graf, T., Konig, B. & Kalbitzer, H.R. A novel mechanism for the modulation of the Ras-efector interaction by small molecules. Biochem. Biophys. Res. Commun. 334, 709-713 (2005).
40. Rosnizeck, I.C. et al. Stabilizing a weak binding state for efectors in the human Ras protein by cyclen complexes. Angew. Chem. Int. Ed. Engl. 49, 3830-3833 (2010).
41. Rosnizeck, I.C. et al. Metal-bis(2-picolyl)amine complexes as state 1(T) inhibitors of activated Ras protein. Angew. Chem. Int. Ed. Engl. 51, 10647-10651 (2012).
42. Tanaka, T., Williams, R.L. & Rabbitts, T.H. Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS. EMBO J. 26, 3250-3259 (2007).
43. Tanaka, T. & Rabbitts, T.H. Interfering with RAS-efector protein interactions prevent RAS-dependent tumour initiation and causes stop-start control of cancer growth. Oncogene 29, 6064-6070 (2010).
44. Barnard, D., Sun, H., Baker, L. & Marshall, M.S. In vitro inhibition of Ras-Raf association by short peptides. Biochem. Biophys. Res. Commun. 247, 176-180 (1998).
45. Wu, X., Upadhyaya, P., Villalona-Calero, M.A., Briesewitz, R. & Pei, D. Inhibition of Ras-efector interactions by cyclic peptides. Med. Chem. Commun. 4, 378 (2013).
46. Pasricha, P.J. et al. Te efects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 109, 994-998 (1995).
47. Herrmann, C. et al. Sulindac sulfde inhibits Ras signaling. Oncogene 17, 1769-1776 (1998).
48. Müller, O. et al. Identifcation of potent Ras signaling inhibitors by pathway-selective phenotype-based screening. Angew. Chem. Int. Ed. Engl. 43, 450-454 (2004).
49. Waldmann, H. et al. Sulindac-derived Ras pathway inhibitors target the Ras-Raf interaction and downstream efectors in the Ras pathway. Angew. Chem. Int. Ed. Engl. 43, 454-458 (2004).
50. González-Pérez, V. et al. Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells. J. Mol. Signal. 5, 2 (2010).
51. Kato-Stankiewicz, J. et al. Inhibitors of Ras/Raf-1 interaction identifed by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells. Proc. Natl. Acad. Sci. USA 99, 14398-14403 (2002).
52. Lu, Y. et al. Solution phase parallel synthesis and evaluation of MAPK inhibitory activities of close structural analogues of a Ras pathway modulator. Bioorg. Med. Chem. Lett. 14, 3957-3962 (2004).
53. Skobeleva, N., Menon, S., Weber, L., Golemis, E.A. & Khazak, V. In vitro and in vivo synergy of MCP compounds with mitogen-activated protein kinase pathway-and microtubule-targeting inhibitors. Mol. Cancer Ter. 6, 898-906 (2007).
54. Shima, F. et al. Structural basis for conformational dynamics of GTP-bound Ras protein. J. Biol. Chem. 285, 22696-22705 (2010).
55. Shima, F. et al. In silico discovery of small-molecule Ras inhibitors that display antitumor activity by blocking the Ras-efector interaction. Proc. Natl. Acad. Sci. USA 110, 8182-8187 (2013).
56. Ahearn, I.M., Haigis, K., Bar-Sagi, D. & Philips, M.R. Regulating the regulator: post-translational modifcation of RAS. Nat. Rev. Mol. Cell Biol. 13, 39-51 (2012).
57. Whyte, D.B. et al. K-and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem. 272, 14459-14464 (1997).
58. Lobell, R.B. et al. Preclinical and clinical pharmacodynamic assessment of l-778, 123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I. Mol. Cancer Ter. 1, 747-758 (2002).
59. Gnant, M. et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N. Engl. J. Med. 360, 679-691 (2009).
60. Jahnke, W. et al. Allosteric non-bisphosphonate FPPS inhibitors identifed by fragment-based discovery. Nat. Chem. Biol. 6, 660-666 (2010).
61. Winter-Vann, A.M. & Casey, P.J. Opinion: post-prenylation-processing enzymes as new targets in oncogenesis. Nat. Rev. Cancer 5, 405-412 (2005).
62. Go, M.-L. et al. Amino derivatives of indole as potent inhibitors of isoprenylcysteine carboxyl methyltransferase. J. Med. Chem. 53, 6838-6850 (2010).
63. Wahlstrom, A.M. et al. Inactivating Icmt ameliorates K-RAS-induced myeloproliferative disease. Blood 112, 1357-1365 (2008).
64. Riely, G.J. et al. A phase II trial of salirasib in patients with lung adenocarcinomas with KRAS mutations. J. Torac. Oncol. 6, 1435-1437 (2011).
65. Laheru, D. et al. Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS, Salirasib) in pancreatic cancer. Invest. New Drugs 30, 2391-2399 (2012).
66. Campbell, P.M. et al. TLN-4601 suppresses growth and induces apoptosis of pancreatic carcinoma cells through inhibition of Ras-ERK MAPK signaling. J. Mol. Signal. 5, 18 (2010).
67. Rocks, O. et al. An acylation cycle regulates localization and activity of palmitoylated Ras isoforms. Science 307, 1746-1752 (2005).
68. Rocks, O., Peyker, A. & Bastiaens Philippe, I.H. Spatio-temporal segregation of Ras signals: one ship, three anchors, many harbors. Curr. Opin. Cell Biol. 18, 351-357 (2006).
69. Rocks, O. et al. Te palmitoylation machinery is a spatially organizing system for peripheral membrane proteins. Cell 141, 458-471 (2010).
70. Dekker, F.J. et al. Small-molecule inhibition of APT1 afects Ras localization and signaling. Nat. Chem. Biol. 6, 449-456 (2010).
71. Rusch, M. et al. Identifcation of acyl protein thioesterases 1 and 2 as the cellular targets of the Ras-signaling modulators palmostatin B and M. Angew. Chem. Int. Edn Engl. 50, 9838-9842 (2011).
72. Hedberg, C. et al. Development of highly potent inhibitors of the Rastargeting human acyl protein thioesterases based on substrate similarity design. Angew. Chem. Int. Edn Engl. 50, 9832-9837 (2011).
73. Adibekian, A. et al. Confrming target engagement for reversible inhibitors in vivo by kinetically tuned activity-based probes. J. Am. Chem. Soc. 134, 10345-10348 (2012).
74. Chandra, A. et al. Te GDI-like solubilizing factor PDEδ sustains the spatial organization and signalling of Ras family proteins. Nat. Cell Biol. 14, 148-158 (2012).
75. Ismail, S.A. et al. Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo. Nat. Chem. Biol. 7, 942-949 (2011).
76. Zimmermann, G. et al. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature 497, 638-642 (2013).
77. Humbert, M.C. et al. ARL13B, PDE6D, and CEP164 form a functional network for INPP5E ciliary targeting. Proc. Natl. Acad. Sci. USA 109, 19691-19696 (2012).
78. Zhang, H., Constantine, R., Frederick, J.M. & Baehr, W. Te prenyl-binding protein PrBP/δ: a chaperone participating in intracellular trafcking. Vision Res. 75, 19-25 (2012).
79. Tomas, S. et al. A homozygous PDE6D mutation in Joubert syndrome impairs targeting of farnesylated INPP5E protein to the primary cilium. Hum. Mutat. 35, 137-146 (2014).
80. Schmick, M. et al. KRas localizes to the plasma membrane by spatial cycles of solubilization, trapping and vesicular transport. Cell 157, 459-471 (2014).
81. Stephen, A.G., Esposito, D., Bagni, R.K. & McCormick, F. Dragging Ras back in the ring. Cancer Cell 25, 272-281 (2014).
82. Young, A., Lou, D. & McCormick, F. Oncogenic and wild-type Ras play divergent roles in the regulation of mitogen-activated protein kinase signaling. Cancer Discov. 3, 112-123 (2013).
83. Bentley, C. et al. A requirement for wild-type Ras isoforms in mutant KRas-driven signalling and transformation. Biochem. J. 452, 313-320 (2013).
84. To, M.D., Rosario, R.D., Westcott, P.M.K., Banta, K.L. & Balmain, A. Interactions between wild-type and mutant Ras genes in lung and skin carcinogenesis. Oncogene 32, 4028-4033 (2013).
85. Grabocka, E. et al. Wild-type H-and N-Ras promote mutant K-Ras-driven tumorigenesis by modulating the DNA damage response. Cancer Cell 25, 243-256 (2014).
86. Luo, F. et al. Wild-type K-ras has a tumour suppressor efect on carcinogen-induced murine colorectal adenoma formation. Int. J. Exp. Pathol. 95, 8-15 (2014).
87. Kleiner, R.E., Dumelin, C.E. & Liu, D.R. Small-molecule discovery from DNA-encoded chemical libraries. Chem. Soc. Rev. 40, 5707-5717 (2011).
88. Murakami, H., Ohta, A., Ashigai, H. & Suga, H. A highly fexible tRNA acylation method for non-natural polypeptide synthesis. Nat. Methods 3, 357-359 (2006).
89. Goto, Y. & Suga, H. Translation initiation with initiator tRNA charged with exotic peptides. J. Am. Chem. Soc. 131, 5040-5041 (2009).
90. Walensky, L.D. & Bird, G.H. Hydrocarbon-stapled peptides: principles, practice, and progress. J. Med. Chem. doi:10.1021/jm4011675 (2014).
91. Kim, Y.-W., Grossmann, T.N. & Verdine, G.L. Synthesis of all-hydrocarbon stapled α-helical peptides by ring-closing olefn metathesis. Nat. Protoc. 6, 761-771 (2011).
92. Spiegel, J. et al. Direct targeting of Rab-GTPase-efector interactions. Angew. Chem. Int. Ed. Engl. 53, 2498-2503 (2014).
93. Ahmadian, M.R. et al. Guanosine triphosphatase stimulation of oncogenic Ras mutants. Proc. Natl. Acad. Sci. USA 96, 7065-7070 (1999).
94. Gail, R., Costisella, B., Ahmadian, M., Reza & Wittinghofer, A. Ras-mediated cleavage of a GTP Analogue by a novel mechanism. ChemBioChem 2, 570-575 (2001).
95. Zhang, H. et al. Deletion of PrBP δ impedes transport of GRK1 and PDE6 catalytic subunits to photoreceptor outer segments. Proc. Natl. Acad. Sci. USA 104, 8857-8862 (2007).
96. Prahallad, A. et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature 483, 100-103 (2012).
97. Kamioka, Y., Yasuda, S., Fujita, Y., Aoki, K. & Matsuda, M. Multiple decisive phosphorylation sites for the negative feedback regulation of SOS1 via ERK. J. Biol. Chem. 285, 33540-33548 (2010).
98. Navas, C. et al. EGF receptor signaling is essential for K-Ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell 22, 318-330 (2012).
99. Nussinov, R., Tsai, C.-J. & Mattos, C. 'Pathway drug cocktail': targeting Ras signaling based on structural pathways. Trends Mol. Med. 19, 695-704 (2013).
100. Hayes, T.K. & Der, C.J. Mutant and wild-type Ras: co-conspirators in cancer. Cancer Discov. 3, 24-26 (2013).
101. Schefzek, K. et al. Te Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science 277, 333-338 (1997).
102. ras in complex with GTP: new insights into the role of water molecules in the GTP hydrolysis reaction of ras-like proteins. Structure 7, 1311-1324 (1999).
103. Buhrman, G., Holzapfel, G., Fetics, S. & Mattos, C. Allosteric modulation of Ras positions Q61 for a direct role in catalysis. Proc. Natl. Acad. Sci. USA 107, 4931-4936 (2010).
104. Muraoka, S. et al. Crystal structures of the state 1 conformations of the GTP-bound H-Ras protein and its oncogenic G12V and Q61L mutants. FEBS Lett. 586, 1715-1718 (2012).